Maven Securities’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Maven Securities’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-55,000	Closed	-$3.23M	–	1073
2023 Q4	$3.23M	Sell	55,000 -35,000	-39%	-$1.97M	0.07%	214
2023 Q3	$3.92M	Buy	+90,000	New	+$3.21M	0.04%	237
2022 Q1	–	Sell	-6,102	Closed	-$895K	–	1152
2021 Q4	$895K	Buy	+6,102	New	+$947K	0.03%	385
2021 Q1	–	Sell	-28,900	Closed	-$6.35M	–	1334
2020 Q4	$6.35M	Buy	+28,900	New	+$6.25M	0.63%	36

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Maven Securities's MRTX Position: Q1 2024 in Review

Maven Securities sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 55,000 shares — an estimated $3.23M sold.

Maven Securities first reported a position in MRTX in Q4 2020 and held it in 4 quarters. The position peaked at $6.35M in Q4 2020. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

Maven Securities reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Maven Securities sold 55,000 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $3.23M.
Maven Securities first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2020 and held it in 4 quarters.
Maven Securities's Mirati Therapeutics, Inc. Common Stock position peaked at $6.35M in Q4 2020.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Maven Securities's 13F filing for Q1 2024, filed 14 May 2024.